Blog
RSS FeedPosted by Michael Wonder on 12 Oct 2021
Deciphera announces approval of Qinlock in Switzerland for the treatment of fourth-line gastro-intestinal stromal tumour
12 October 2021 - Seventh approval worldwide for Qinlock and first European approval. ...
Posted by Michael Wonder on 27 Aug 2021
BioCryst announces acceptance of regulatory applications for Orladeyo (berotralstat) by Health Canada and Swissmedic
25 August 2021 - BioCryst Pharmaceuticals today announced that the new drug submission for Orladeyo (berotralstat) has been accepted for ...
Posted by Michael Wonder on 24 Aug 2021
Clovis Oncology announces availability of and reimbursement for Rubraca (rucaparib) tablets for women with relapsed ovarian cancer in Switzerland
24 August 2021 - Rubraca is commercially available in Germany, United Kingdom, Italy, Spain, France, Netherlands, United States of America and ...
Posted by Michael Wonder on 19 Aug 2021
BeiGene announces acceptance by Swissmedic of marketing authorisation application for Brukinsa (zanubrutinib) in Waldenström’s macroglobulinaemia
18 August 2021 - BeiGene announced that Swissmedic has accepted the marketing authorisation application for Brukinsa, a treatment option for adult ...
Posted by Michael Wonder on 10 Aug 2021
Moderna COVID-19 vaccine gets Swiss approval for 12 to 17 year-olds
9 August 2021 - Swissmedic has approved the Moderna COVID-19 vaccine for 12- to 17-year-olds, the Swiss agency said on ...
Posted by Michael Wonder on 16 Jun 2021
Emmaus Life Sciences announces submission of marketing authorisation application to Swissmedic; Ideogen to manage early access program
15 June 2021 - Emmaus Life Sciences anounced today it has received confirmation from the Swiss Agency for Therapeutic Products ...
Posted by Michael Wonder on 15 Jun 2021
Moderna seeks vaccine approval for adolescents
11 June 2021 - US-based biotech company Moderna is applying for the use of its COVID-19 vaccine for adolescents aged 12 ...
Posted by Michael Wonder on 21 Apr 2021
Switzerland ‘unfortunately’ still awaiting AstraZeneca COVID-19 vaccine data
21 April 2021 - Switzerland’s drug regulator is still awaiting data needed to consider whether to approve AstraZeneca’s COVID-19 vaccine, ...
Posted by Michael Wonder on 20 Apr 2021
CureVac Swiss initiates rolling submission process for mRNA-based COVID-19 vaccine candidate, CVnCoV, with Swissmedic
19 April 2021 - Review process started with submission of first CVnCoV data package. ...
Posted by Michael Wonder on 23 Mar 2021
Johnson & Johnson Covid vaccine approved for use in Switzerland
22 March 2021 - Health regulator Swissmedic has given the green light for the use of the vaccine produced by Johnson ...
Posted by Michael Wonder on 19 Mar 2021
Data on AstraZeneca vaccine insufficient for Swiss approval
18 March 2021 - The medicines regulator Swissmedic says it has not yet received enough robust data from clinical trials ...
Posted by Michael Wonder on 22 Feb 2021
Switzerland could sell or give away AstraZeneca doses if regulator dithers
21 February 2021 - A lack of green light from medicines regulator SwissMedic could see 5.3 million doses ordered by Switzerland ...
Posted by Michael Wonder on 04 Feb 2021
Swiss medical regulator rejects Oxford/AstraZeneca COVID-19 vaccine
3 February 2021 - Switzerland’s medical regulator has said it cannot authorise use of the Oxford/AstraZeneca Covid-19 vaccine based on ...
Posted by Michael Wonder on 13 Jan 2021
Swissmedic authorises COVID-19 Vaccine Moderna for use in Switzerland
12 January 2021 - Swiss Federal Government has secured 7.5 million doses and first deliveries expected to begin in January. ...
Posted by Michael Wonder on 06 Jan 2021
MorphoSys and Incyte announce the acceptance of the Swissmedic marketing authorisation application for tafasitamab
5 January 2021 - The Swissmedic marketing authorisation application seeks approval for tafasitamab in combination with lenalidomide for the treatment ...